BioXcel Therapeutics has released its Q3 2025 financial results, reporting a decrease in net revenue from IGALMI® but also significantly reduced cost of goods sold. The company increased R&amp;D expenses due to heightened clinical trial activity while decreasing SG&amp;A expenses. BioXcel Therapeutics is advancing its late-stage clinical programs, including the SERENITY At-Home Phase 3 Safety Trial and the TRANQUILITY In-Care Phase 3 Trial, and plans to submit a supplemental New Drug Application (sNDA) in early Q1 2026 for the at-home use of IGALMI®.

BTAI

<p>BioXcel Therapeutics 發佈了其 2025 年第三季度財務業績，報告顯示 IGALMI® 的淨收入有所下降，但銷售成本顯著降低。由於臨牀試驗活動增加，公司增加了研發費用，同時減少了銷售及管理費用。BioXcel Therapeutics 正在推進其晚期臨牀項目，包括 SERENITY 在家階段 3 安全試驗和 TRANQUILITY 在護理階段 3 試驗，並計劃在 2026 年第一季度初提交 IGALMI® 在家使用的補充新藥申請（sNDA）</p>

Bioxcel Therapeutics 2025 年第三季度財務業績及臨牀項目更新